Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - phentermine, quantity: 15 mg - capsule, modified release - excipient ingredients: sodium polystyrene sulfonate; magnesium stearate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; gelatin; ethanol absolute - phentermine gh is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater. the treatment with phentermine gh can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2), which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - phentermine, quantity: 40 mg - capsule, modified release - excipient ingredients: magnesium stearate; sodium polystyrene sulfonate; titanium dioxide; purified water; erythrosine; gelatin; iron oxide black; patent blue v; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; potassium hydroxide; ethanol absolute - phentermine gh is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater. the treatment with phentermine gh can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2), which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - phentermine, quantity: 30 mg - capsule, modified release - excipient ingredients: magnesium stearate; sodium polystyrene sulfonate; titanium dioxide; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; ethanol absolute; ammonia; potassium hydroxide; brilliant blue fcf; erythrosine; gelatin; iron oxide black - phentermine gh is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater. the treatment with phentermine gh can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2), which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - escitalopram oxalate -

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - escitalopram oxalate -

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - escitalopram oxalate -

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - escitalopram oxalate -

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - escitalopram oxalate -

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - escitalopram oxalate -

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - escitalopram oxalate, quantity: 25.54 mg (equivalent: escitalopram, qty 20 mg) - tablet, film coated - excipient ingredients: purified talc; microcrystalline cellulose; magnesium stearate; croscarmellose sodium; colloidal anhydrous silica; titanium dioxide; hypromellose; macrogol 400 - - treatment of major depression. - treatment of social anxiety disorder (social phobia). - treatment of generalised anxiety disorder. - treatment of obsessive-compulsive disorder.